The assessment of trabecular bone score to improve the sensitivity of FRAX in patients with type 2 diabetes mellitus
https://doi.org/10.14341/osteo12464
Abstract
Aim. To estimate the trabecular bone score (TBS) for evaluation of fracture probability in order to make decisions about starting osteoporosis treatment in patients with type 2 diabetes mellitus (T2DM).
Materials and methods. We obtained the bone mineral density (BMD) and trabecular bone score (TBS) using dual energy X-ray absorptiometry (iDXA) in patients with T2DM (with and without a history of osteoporotic fractures) versus the control group. Before and after TBS measurements we assessed the ten-year probability of fracture using the Fracture Risk Assessment Tool (FRAX).
Results. We enrolled 48 patients with T2DM, including 17 with a history of low-traumatic fracture, 31 patients without fractures and 29 subjects of a control group. BMD was higher in patients with T2DM compared to the control group at L1–L4 (mean T-score 0.44, 95% CI -3.2 – 4.9 vs mean T-score 0.33, 95% CI -2.9 – 3.0 in a control group p=0.052) and Total Hip (mean T-score 0.51, 95% CI -2.1 – 3.0 vs mean T-score -0.03, 95% CI -1.4 – 1.2 in a control group p=0,025). The TBS and 10-year probability of fracture (FRAX) was not different in patients with T2DM versus the control group. However, when the TBS was entered as an additional risk factor, the 10-year probability of fracture became higher in patients with T2DM (10-year probability of fracture in T2DM- 8.68, 95% CI 0.3-25.0 versus 6.68, 95% CI 0.4–15.0 in control group, p=0.04). Among patients with diabetes with and without fractures the FRAX score was higher in subjects with fractures, but no difference was found in regards to BMD or TBS. Entering BMD and TBS values into the FRAX tool in subjects with diabetes and fractures decreased the FRAX score. However, patients with low-traumatic fractures should be treated for osteoporosis without a BMD, TBS or FRAX assessment.
Conclusion. TBS improves the results of FRAX assessment in patients with T2DM and should be entered while evaluating FRAX in patients with T2DM. However, additional research is needed to develop a more sensitive tool to evaluate fracture risk in patients with T2DM.
About the Authors
Tatiana O. YalochkinaRussian Federation
MD, endocrinologist
Competing Interests:
The research is part of the dissertation work of T.O. Yalochkina.
Zhanna E. Belaya
Russian Federation
MD, PhD, Professor
Tatiana O. Chernova
Russian Federation
MD, PhD
Natalia I. Sazonova
Russian Federation
MD, PhD
Natalya V. Tarbaeva
Russian Federation
MD, PhD
Timur T. Tsoriev
Russian Federation
Research Scientist, Department of Neuroendocrinology and Bone Diseases, Institute for Clinical Endocrinology
Liudmila Y. Rozhinskaya
Russian Federation
MD, Professor, Chief Researcher of the
Department of Neuroendocrinology and Osteopathy
Galina A. Melnichenko
Russian Federation
MD, PhD, Professor
References
1. Koh WP, Wang R, Ang LW, et al. Diabetes and Risk of Hip Fracture in the Singapore Chinese Health Study. Diabetes Care. 2010;33(8):1766-1770. doi: 10.2337/dc10-0067.
2. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and Its Complications and Their Relationship with Risk of Fractures in Type 1 and 2 Diabetes. Calcif Tissue Int. 2008;84(1):45-55. doi: 10.1007/s00223-008-9195-5.
3. Bonds DE, Larson JC, Schwartz AV, et al. Risk of Fracture in Women with Type 2 Diabetes: the Women’s Health Initiative Observational Study. J Clin Endocr Metab. 2006;91(9):3404-3410. doi: 10.1210/jc.2006-0614.
4. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2006;18(4):427-444. doi: 10.1007/s00198-006-0253-4.
5. Ялочкина Т.О., Белая Ж.Е., Рожинская Л.Я., и др. Переломы костей при сахарном диабете 2 типа: распространенность и факторы риска. // Сахарный диабет. – 2016. – Т. 19. – № 5. – С. 359-365. [Yalochkina TO, Belaya JEe, Rozhinskaya LY, et al. Bone fractures in patients with type 2 diabetes mellitus: prevalence and risk factors. Diabetes mellitus. 2016;19(5):359-365. (in Russ.)] doi: 10.14341/dm7796.
6. Цориев Т.Т., Белая Ж.Е., Мельниченко Г.А. Трабекулярный костный индекс – неинвазивный метод оценки качества костной ткани на основании рутинной двухэнергетической денситометрии. Перспективы использования в клинической практике. // Альманах Клинической Медицины. – 2016. – Т. 44. – № 4. – С. 462-476. [Tsoriev TT, Belaya ZE, Mel’nichenko GA. Trabecular Bone Score – A non-Invasive Analytical Method to Evaluate Bone Quality Based on Routine Dual-Energy Absorptiometry. Perspectives of Its Use in Clinical Practice. Almanac of Clinical Medicine. 2016;44(4):462-476. (in Russ.)] doi: 10.18786/2072-0505-2016-44-4-462-476.
7. Hans D, Barthe N, Boutroy S, et al. Correlations Between Trabecular Bone Score, Measured Using Anteroposterior Dual-Energy X-Ray Absorptiometry Acquisition, and 3-Dimensional Parameters of Bone Microarchitecture: An Experimental Study on Human Cadaver Vertebrae. J Clin Densitom. 2011;14(3):302-312. doi: 10.1016/j.jocd.2011.05.005.
8. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., и др. Краткое изложение клинических рекомендаций по диагностике и лечению остеопороза Российской Ассоциации Эндокринологов. // Остеопороз и Остеопатии. – 2016. – № 3. – С. 28-36. [Melnichenko GA, Belaya ZE, Rozhinskaya LY, et al. Summary of Clinical Guidelines for the Diagnosis and Treatment of Osteoporosis of the Russian Association of Endocrinologists. Osteoporosis and bone diseases. 2016;19(3):28-36. (in Russ.)] doi: 10.14341/osteo2016328-36.
9. Белая Ж.Е., Смирнова О.М., Дедов И.И. Роль физических нагрузок в норме и при сахарном диабете. // Проблемы эндокринологии. – 2005. – Т.51. - №2. – С. 28-37. [Belaya ZhE, Smirnova OM, Dedov II. Rol’ fizicheskikh nagruzok v norme i pri sakharnom diabete. Problems of endocrinology. 2005;51(2):28-37. (In Russ.)]
10. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes Is Associated Independently of Body Composition With BMD and Bone Volume in Older White and Black Men and Women: The Health, Aging, and Body Composition Study. J Bone Miner Res. 2004;19(7):1084-1091. doi: 10.1359/jbmr.040311.
11. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of Fracture. Am J Epidemiol. 2007;166(5):495-505. doi: 10.1093/aje/kwm106.
12. Rabier B, Héraud A, Grand-Lenoir C, et al. A multicentre, retrospective case–control study assessing the role of trabecular bone score (TBS) in menopausal Caucasian women with low areal bone mineral density (BMDa): Analysing the odds of vertebral fracture. Bone. 2010;46(1):176-181. doi: 10.1016/j.bone.2009.06.032.
13. Winzenrieth R, Dufour R, Pothuaud L, Hans D. A Retrospective Case–Control Study Assessing the Role of Trabecular Bone Score in Postmenopausal Caucasian Women with Osteopenia: Analyzing the Odds of Vertebral Fracture. Calcif Tissue Int. 2009;86(2):104-109. doi: 10.1007/s00223-009-9322-y.
14. Zhukouskaya VV, Ellen-Vainicher C, Gaudio A, et al. The utility of lumbar spine trabecular bone score and femoral neck bone mineral density for identifying asymptomatic vertebral fractures in well-compensated type 2 diabetic patients. Osteoporos Int. 2015;27(1):49-56. doi: 10.1007/s00198-015-3212-0.
15. Hans D, Šteňová E, Lamy O. The Trabecular Bone Score (TBS) Complements DXA and the FRAX as a Fracture Risk Assessment Tool in Routine Clinical Practice. Current Osteoporosis Reports. 2017;15(6):521-531. doi: 10.1007/s11914-017-0410-z.
16. Kanis JA, McCloskey EV, Johansson H, et al. Development and use of FRAX® in osteoporosis. Osteoporos Int. 2010;21(S2):407-413. doi: 10.1007/s00198-010-1253-y.
17. Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А.. Ибандронат (Бонвива) – новое направление в лечении бисфосфонатами. Лучшая приверженность к лечению – лучший результат. // Остеопороз и остеопатии. – 2006. – № 3. – С. 23-29. [Belaya ZE, Rozhinskaya LY, Melnichenko GA. Ibandronat (Bonviva) – novoe napravlenie v lechenii bisfosfonatami. Luchshaya priverzhennost’ k lecheniyu – luchshiy rezul’tat. Osteoporosis and bone diseases. 2006;9(3):23-30. (In Russ.)] doi: 10.14341/osteo2006323-30.
Supplementary files
|
1. Figure: 1. Determination of the trabecular bone index in a patient with type 2 diabetes mellitus. | |
Subject | ||
Type | Other | |
View
(532KB)
|
Indexing metadata ▾ |
|
2. Figure: 2. Determination of further tactics of patient management based on FRAX data. | |
Subject | ||
Type | Other | |
View
(136KB)
|
Indexing metadata ▾ |
|
3. Figure: 3. Composition of the study group. | |
Subject | ||
Type | Other | |
View
(86KB)
|
Indexing metadata ▾ |
|
4. Figure: 4. Individual 10-year probability of fracture (FRAX) in patients with type 2 diabetes mellitus when corrected for trabecular bone index | |
Subject | ||
Type | Other | |
View
(144KB)
|
Indexing metadata ▾ |
Review
For citations:
Yalochkina T.O., Belaya Zh.E., Chernova T.O., Sazonova N.I., Tarbaeva N.V., Tsoriev T.T., Rozhinskaya L.Y., Melnichenko G.A. The assessment of trabecular bone score to improve the sensitivity of FRAX in patients with type 2 diabetes mellitus. Osteoporosis and Bone Diseases. 2019;22(4):4-11. (In Russ.) https://doi.org/10.14341/osteo12464

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).